| Post-Traumatic Stress Disorder |
1 |
1 |
| Psychotherapy |
0 |
0.51 |
| Receptors |
0 |
0.51 |
| Brain |
0 |
0.31 |
| Clinical Research |
0 |
0.31 |
| Alabama |
0 |
0.2 |
| Stimulants |
0 |
0.2 |
| Healthcare and Medical Technology |
0 |
0.13 |
| Agitation |
0 |
0.1 |
| Antidepressant drug |
0 |
0.1 |
| Board Certification |
0 |
0.1 |
| Dementia |
0 |
0.1 |
| Disability |
0 |
0.1 |
| Dopamine |
0 |
0.1 |
| Food and Drug Administration (FDA) |
0 |
0.1 |
| Generics |
0 |
0.1 |
| Geriatrics |
0 |
0.1 |
| Hospital |
0 |
0.1 |
| Injury |
0 |
0.1 |
| Medical Innovations |
0 |
0.1 |
| Memory |
0 |
0.1 |
| Ohio |
0 |
0.1 |
| Orbit |
0 |
0.1 |
| Peer Review |
0 |
0.1 |
| Psychopharmacology |
0 |
0.1 |
| Remission |
0 |
0.1 |
| Sleep |
0 |
0.1 |
| Stress |
0 |
0.1 |
| Major Depression |
0 |
0.09 |
| Traumatic Brain Injury |
0 |
0.07 |
| Depression |
0 |
0.06 |